Johnc Byrd News Today

/PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its...

/PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule...

/PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant achievement in collaboration with Eilean Therapeutics...

/PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule...

<p>A new targeted drug, studied by researchers at <a href="https://cancer.osu.edu/">The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)</a>, may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments....

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

VINC | Complete Vincerx Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Emphasis on novel biological approaches in treating patients with hematologic malignancies

The FDA has approved a new tablet formulation of Calquence (acalabrutinib) for CLL, SLL, and relapsed or refractory MCL.

The FDA has approved a new tablet formulation of Calquence (acalabrutinib) for CLL, SLL, and relapsed or refractory MCL.